

FRIULCHEM ENTERS ASSOAIM, AIM ITALIA ISSUERS ASSOCIATION

Milan, 15 April 2020 - **Friulchem S.p.A.** (AIM: FCM), innovative SME and one of the main Italian operators at international level in R&D and in the production on behalf of third parties (CDMO) of semi-finished and finished products containing pharmaceutical active ingredients, dietary supplements, specialising in particular in drug delivery for the veterinary sector, **announces that it has joined AssoAim, the Aim Italia Issuers Association.**

"We strongly wanted to join AssoAim - comments Disma Giovanni Mazzola, CEO of Friulchem - a structure that we consider strategic for the evolution and growth of the AIM market, in which we landed last year. We have enthusiastically chosen to land in this market managed by Borsa Italiana, dedicated to companies with high growth potential, because we believe it is the best possible path for companies that want to evolve both on the Governance and on the business side. Our experience is certainly positive, the listing was a fundamental boost to close strategic agreements and extraordinary operations such as the purchase of 13% of Pharmabbie in the USA. Thanks to AssoAim - Mazzola continues - we think we can give our contribution to the spread and growth of the AIM market aimed at Italian SMEs, in particular in the North East where we are located with a highly innovative plant".

Founded in October 2019, AssoAim's main objective is the study, dissemination and treatment of issues related to the trading of financial instruments on AIM Italia and other multilateral trading systems (MTF), acting as a reference interlocutor representing the interests of companies listed and listed-to-be on the AIM market, in institutional offices and vis-à-vis supervisory authorities. The Association's attention is mainly focused on corporate governance issues, transparency obligations, relations with entrepreneurs, shareholders, investors, operators and stakeholders, and the requirements for access and permanence on the market.

The press release is available on the website <https://friulchem.com/it/media-relations/>

Friulchem (AIM:FCM), a company that has been operating in this sector for over 20 years, is today one of Italy's leading CDMOs (*Contract Development Manufacturing Organisations*) operating internationally in the healthcare sector. It offers third-party research, development and manufacturing services for semi-finished and finished products containing both active pharmaceutical ingredients and food supplements. It primarily specialises in drug delivery systems for the veterinary sector, providing Friulchem's trademark excellence, as well as in the development of dossiers for generic medicines for human use. Friulchem is an innovative SME and B2B company which prides itself on its end-customer focus, and has deep Italian roots, thanks to its manufacturing facilities in Vivaro (Pordenone) and administrative headquarters in Milan. The Company is strongly oriented towards R&D activities and boasts established relationships with leading multinational companies in the pharmaceutical sector.

Common Shares ISIN: IT0005378457 - Friulchem Warrant ISIN: 2019-2022 IT0005378366

Friulchem S.p.A.

ir@friulchem.com

Tel: +39 02 36591450

CDR Communication - Investor and Media Relations

Silvia Di Rosa silvia.dirosa@cdr-communication.it

Marianna Tremolada marianna.tremolada@cdr-communication.it